Merrimack Pharmaceuticals Shares Fall Amid End Of MM-121 Collaboration With Sanofi

By Dow Jones Business News, 
A A A


By Anna Prior

Merrimack Pharmaceuticals Inc. ( MACK ) and Sanofi ( SNY ) have terminated their license and collaboration agreement for the development and commercialization of Merrimack's antibody MM-121 to treat different forms of cancer.

Merrimack shares slumped 15% to $6.70 in recent after-hours trading.

Sanofi will continue to fund the existing MM-121 Phase 2 program for the next six months, said Merrimack, adding that the final study completed through this collaboration is a test of MM-121 in combination with paclitaxel in patients with triple negative breast cancer.

Merrimack plans to look for other strategic partnership opportunities as it continues to develop MM-121, said Chief Executive Robert Mulroy, noting that the company's next step includes discussing Phase 2 data and potential registration paths with the U.S. Food and Drug Administration.

In October, Merrimack said a Phase 2 study of the antibody to treat ovarian cancer didn't meet the primary endpoint of progression free survival in the overall population. The company was studying MM-121 in combination with paclitaxel versus paclitaxel alone in patients with platinum-resistant or platinum-refractory advanced ovarian cancers.

Write to Anna Prior at anna.prior@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


  (END) Dow Jones Newswires
  06-19-141752ET
  Copyright (c) 2014 Dow Jones & Company, Inc.


This article appears in: News Headlines

Referenced Stocks: MACK , SNY

Dow Jones Business News


More from Dow Jones Business News:

Related Videos

Stocks

Referenced

100%
100%

Most Active by Volume

88,066,694
  • $97.19 ▲ 2.61%
58,241,731
  • $71.29 ▲ 2.92%
51,058,864
  • $44.87 ▲ 0.09%
48,927,829
  • $28.75 ▲ 0.81%
46,551,917
    $15.52 unch
40,249,498
  • $3.46 ▼ 0.57%
38,633,031
  • $22.43 ▼ 9.63%
38,240,825
  • $34.71 ▲ 3.30%
As of 7/23/2014, 04:04 PM